139 related articles for article (PubMed ID: 3303928)
41. Tumor-related osteomalacia followed after treatment by hyperparathyroidism.
Heylen A; Dasnoy D; Hustin J; Pochet JM
Rev Rhum Engl Ed; 1999 Jan; 66(1):53-7. PubMed ID: 10036701
[TBL] [Abstract][Full Text] [Related]
42. [Hyperparathyroidism masked by osteomalacia. Is vitamin D administration in every case of osteomalacia problem-free?].
Zuber M; Löliger M; Boner H; Haas HG
Schweiz Med Wochenschr; 1986 May; 116(19):642-7. PubMed ID: 3715442
[TBL] [Abstract][Full Text] [Related]
43. Tumor-induced osteomalacia: clinical and basic studies.
Shane E; Parisien M; Henderson JE; Dempster DW; Feldman F; Hardy MA; Tohme JF; Karaplis AC; Clemens TL
J Bone Miner Res; 1997 Sep; 12(9):1502-11. PubMed ID: 9286768
[TBL] [Abstract][Full Text] [Related]
44. Pathologic quiz case. A 36-year-old woman with muscle pain and weakness. Phosphaturic mesenchymal tumor (mixed connective tissue variant)/oncogenic osteomalacia.
Reis-Filho JS; Paiva ME; Lopes JM
Arch Pathol Lab Med; 2002 Oct; 126(10):1245-6. PubMed ID: 12385334
[No Abstract] [Full Text] [Related]
45. Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report.
Tartaglia F; Minisola S; Sgueglia M; Blasi S; Brunelli D; Degli Effetti E; Maturo A; Cola A; Custureri F; Campana FP
G Chir; 2006; 27(1-2):9-13. PubMed ID: 16608626
[TBL] [Abstract][Full Text] [Related]
46. [Hyperparathyroidism associated with hypophosphatemic osteomalacia: case report and review of the literature].
Moreira RO; Leal CT; Lacativa PG; Figueiredo JG; Lima MB; Farias ML
Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):150-5. PubMed ID: 16628288
[TBL] [Abstract][Full Text] [Related]
47. Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone.
Drezner MK; Feinglos MN
J Clin Invest; 1977 Nov; 60(5):1046-53. PubMed ID: 908749
[TBL] [Abstract][Full Text] [Related]
48. [Oncogenic osteomalacic myopathy; a case report].
Urushitani M; Nishinaka K; Udaka F; Kameyama M
Rinsho Shinkeigaku; 1995 Feb; 35(2):195-200. PubMed ID: 7781239
[TBL] [Abstract][Full Text] [Related]
49. Tumor induced osteomalacia.
Ioakimidis DE; Dendrinos GK; Frangia KB; Babiolakis DN; Chilas GI; Lyberopoulos KL; Kontomerkos TK
J Rheumatol; 1994 Jun; 21(6):1162-4. PubMed ID: 7932437
[TBL] [Abstract][Full Text] [Related]
50. Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: case report and review of the literature.
Peterson NR; Summerlin DJ; Cordes SR
Ear Nose Throat J; 2010 Jun; 89(6):E11-5. PubMed ID: 20556724
[TBL] [Abstract][Full Text] [Related]
51. Severe hypophosphataemic osteomalacia with primary hyperparathyroidism.
Woodhead JS; Ghose RR; Gupta SK
Br Med J; 1980 Sep; 281(6241):647-8. PubMed ID: 6969103
[No Abstract] [Full Text] [Related]
52. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
53. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
Hernandez JD; Wesseling K; Boechat MI; Gales B; Salusky IB
Nat Clin Pract Nephrol; 2007 Apr; 3(4):227-32. PubMed ID: 17389892
[TBL] [Abstract][Full Text] [Related]
54. Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy.
Yoshioka K; Nagata R; Ueda M; Yamaguchi T; Konishi Y; Hosoi M; Inoue T; Yamanaka K; Iwai Y; Sato T
Intern Med; 2006; 45(20):1157-60. PubMed ID: 17106161
[TBL] [Abstract][Full Text] [Related]
55. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.
Bai X; Miao D; Li J; Goltzman D; Karaplis AC
Endocrinology; 2004 Nov; 145(11):5269-79. PubMed ID: 15284207
[TBL] [Abstract][Full Text] [Related]
56. Oncogenous osteomalacia and malignancy.
Harvey JN; Gray C; Belchetz PE
Clin Endocrinol (Oxf); 1992 Oct; 37(4):379-82. PubMed ID: 1483296
[TBL] [Abstract][Full Text] [Related]
57. Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism.
Hodsman AB; Sherrard DJ; Wong EG; Brickman AS; Lee DB; Alfrey AC; Singer FR; Norman AW; Coburn JW
Ann Intern Med; 1981 May; 94(5):629-37. PubMed ID: 6894520
[TBL] [Abstract][Full Text] [Related]
58. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
59. Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia.
Yeung SJ; McCutcheon IE; Schultz P; Gagel RF
J Clin Endocrinol Metab; 2000 Feb; 85(2):549-55. PubMed ID: 10690854
[TBL] [Abstract][Full Text] [Related]
60. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
